Chief Development Officer (CDO)
Manfred has more than twenty years of experience in pharmaceutical and biotech industry. As CEO, COO or program manager, he co-founded or developed the biotech companies Igeneon AG, Apeiron Biologics AG, RMB Research and RemuteBio.
At Origimm, Manfred is responsible for the non-clinical and pre-clinical activities required for the product characterization, development and clinical trial approval. He is also managing various external collaborations, internal infrastructure and regulatory operations.
Manfred is certified as Qualified Person, holds a PhD degree from the University of Natural Resources of Vienna, a Master of Science Engineer degree in technical chemistry, biochemistry and biotechnology from the Technical University of Vienna and a Master of Science degree in pharmaceutical quality management from the University of Vienna.
Manfred worked many years as the executive board member and program manager for early and late stage clinical development programs against cancer, including vaccines and antibody therapeutics. He developed an orphan antibody-based immuno-therapy against neuroblastoma until submission for market approval in Europe, and enzyme substitution therapy from the idea until an exclusive license deal of € 250 M with Glaxo-SmithKline in Phase II.
Besides working hard on improving the lives of patients, Manfred is also contributing to societal values as a qualified fire safety engineer and lifeguard trainer.